Table 4.
Comparison of clinicopathologic parameters between ER and LTS groups
| Groups | ER (N = 28) | 3-year LTS (N = 28) | p vs ER | 5-year LTS (N = 20) | p vs ER |
|---|---|---|---|---|---|
| Sex (female) | 22 | 23 | 1 | 17 | 0.716 |
| Age (years) | 50.07 [51 (30–72)] | 57 [62(26–78)] | 0.09 | 58.7 [63 (28–78)] | 0.061 |
| < 30 | 0 | 2 | 1 | ||
| 30–60 | 24 | 11 | 7 | ||
| > 60 | 4 | 15 | 12 | ||
| Continuous variables | mean (median [range]) | mean (Median [range]) | |||
| BMI | 24.6 [24.2 (16.8–34.4)] | 24.4 [24 (18–37)] | 0.72 | 23.54 [23.98 (18.6–27.5)] | 0.403 |
| ASA score | 0.861 | 0.859 | |||
| 1 | 1 | 1 | 1 | ||
| 2 | 22 | 23 | 16 | ||
| 3 | 4 | 4 | 3 | ||
| 4 | 1 | 0 | 0 | ||
| Type of primary | 0.226 | 0.396 | |||
| Breast | 18 | 17 | 13 | ||
| Squamous origin | 0 | 2 | 2 | ||
| Melanoma | 2 | 1 | 1 | ||
| Genito-urinary | 2 | 5 | 3 | ||
| Sarcoma | 2 | 3 | 1 | ||
| Gastro-intestinal | 3 | 0 | 0 | ||
| Esophagus | 1 | 0 | 0 | ||
| Disease-free interval | 0.533 | 0.281 | |||
| 0–12 months | 13 | 10 | 7 | ||
| 12–24 months | 2 | 1 | 0 | ||
| > 24 months | 13 | 17 | 13 | ||
| AFC score | 0.64 | 0.727 | |||
| 1 | 5 | 4 | 2 | ||
| 2 | 2 | 4 | 4 | ||
| 3 | 6 | 9 | 5 | ||
| 4 | 9 | 4 | 4 | ||
| 5 | 5 | 6 | 4 | ||
| 6 | 1 | 1 | 1 | ||
| AFC score cat | 0.422 | 0.770 | |||
| Low/intermediate risk | 13/15 | 17/11 | 11/ 9 | ||
| Size of metastasis at diagnosis (mm) | 37.8 [35 (12–70)] | 33 [24(10–104)] | 0.058 | 30.8 [24 (10–100)] | 0.041 |
| Size of metastasis pre-op (mm) | 34.18 [34 (8–65)] | 29.6 [22(3–100)] | 0.166 | 29.4 [22 (3–100)] | 0.143 |
| Diam > 50 mm | 9 | 6 | 0.547 | 4 | 0.512 |
| Number of LM | 2.25 [2 (1–5)] | 2 [1(1–9)] | 0.104 | 2.25 [1 (1–9)] | 1 |
| Number of LM pre-op | 2.07 [2 (1–4)] | 1.7 [1(1–9)] | 0.021 | 1.95 [1 (1–9)] | 0.792 |
| Multinodular metastasis | 18 | 14 | 0.418 | 9 | 0.242 |
| Positive LN status of primary | 18 | 7 | 0.002 | 5 | 0.007 |
| Synchronous (< 12 months) | 13 | 10 | 0.135 | 6 | 0.370 |
| mCRS | 0.132 | 0.190 | |||
| 0 | 3 | 7 | 6 | ||
| 1 | 8 | 10 | 6 | ||
| 2 | 5 | 7 | 5 | ||
| 3 | 9 | 4 | 3 | ||
| 4 | 3 | 0 | 0 | ||
| mCRS cat | 0.037 | 0.059 | |||
| Low-/high risk | 16 /12 | 24 | 17/ 3 | ||
| RF | 10 | 5 | 0.371 | 3 | 0.354 |
| Major hepatectomy | 7 | 7 | 1 | 5 | 1 |
| Post-operative complications | 5 | 6 | 0.6 | 3 | 0.683 |
| Clavien-Dindo | 0.34 | 0.195 | |||
| I–II | 3 | 3 | 3 | ||
| IIIa | 2 | 1 | 0 | ||
| Primary | |||||
| NACT | 15 | 6 | 0.026 | 6 | 0.144 |
| ACT | 22 | 18 | 0.375 | 13 | 0.339 |
| Hormonal therapy | 13 | 15 | 0.79 | 12 | 0.394 |
| Radiotherapy | 15 | 14 | 1 | 11 | 1 |
| Immunotherapy | 0.449 | 0.676 | |||
| No | 19 | 18 | 13 | ||
| Trastuzumab | 8 | 6 | 5 | ||
| Glivec | 1 | 2 | 1 | ||
| Other | 0 | 2 | 1 | ||
| Liver metastasis | |||||
| NACT | 24 | 23 | 1 | 17 | 1 |
| ACT | 21 | 13 | 0.09 | 10 | 0.208 |
RFS relapse-free survivors, BMI body mass index, ASA American Society of Anesthesia, LN lymph node, LM liver metastases, mCRS modified clinical risk score, RF radiofrequency destruction, ACT adjuvant chemotherapy, NACT neoadjuvant chemotherapy, ER early relapse, LTS long-term survivors